Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Over the past several years, there have been major advances in cardiovascular positron emission tomography (PET) in combination with either computed tomography (CT) or, more recently, cardiovascular magnetic resonance (CMR). These multi-modality approaches have significant potential to leverage the strengths of each modality to improve the characterization of a variety of cardiovascular diseases and to predict clinical outcomes. This review will discuss current developments and potential future uses of PET/CT and PET/CMR for cardiovascular applications, which promise to add significant incremental benefits to the data provided by each modality alone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039566 | PMC |
| http://dx.doi.org/10.3390/diagnostics6030032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of F-FAPI-42 PET for Detecting Cardiac Fibroblast Activation in Dilated Cardiomyopathy With Histopathology and CMR.
JACC Cardiovasc Imaging
September 2025
Department of Nuclear Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Electronic address:
Background: Myocardial fibrosis (MF) is a key pathophysiological characteristic of dilated cardiomyopathy (DCM). Radiolabeled imaging agents targeting fibroblast activation protein (FAP) enhance the accuracy and sensitivity for detecting early-stage myocardial fibrosis.
Objectives: This study aimed to evaluate the feasibility of using F-labeled FAP inhibitor tracer (FAPI-42) positron emission tomography (PET) imaging for detecting myocardial fibroblast activation and fibrosis in DCM patients.
Exploring the latest advances in F-FDG PET/CT and cardiac magnetic resonance for imaging for cardiac sarcoidosis diagnosis.
Am J Nucl Med Mol Imaging
April 2024
Department of Internal Medicine, Stony Brook University Hospital Stony Brook, New York, The United States.
Sarcoidosis is a systemic inflammatory disease that affects multiple organs. Various clinical signs are associated with cardiac sarcoidosis (CS), and the diagnosis process is complicated because any organ could be involved. Despite the critical clinical importance of early and precise diagnosis of CS, there is currently no gold-standard method for CS evaluation.
View Article and Find Full Text PDFThe usefulness of repeated CMR and FDG PET/CT in the diagnosis of patients with initial possible cardiac sarcoidosis.
EJNMMI Res
December 2021
Department of Cardiology, St. Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435CM, Nieuwegein, Utrecht, The Netherlands.
Background: Cardiac sarcoidosis (CS) diagnosis is usually based on advanced imaging techniques and multidisciplinary evaluation. Diagnosis is classified as definite, probable, possible or unlikely. If diagnostic confidence remains uncertain, cardiac imaging can be repeated.
View Article and Find Full Text PDFHybrid Cardiac Magnetic Resonance/Fluorodeoxyglucose Positron Emission Tomography to Differentiate Active From Chronic Cardiac Sarcoidosis.
JACC Cardiovasc Imaging
March 2022
Department of Diagnostic and Interventional Radiology, University of Tübingen, Tübingen, Germany.
Objectives: The purpose of this study was to investigate the diagnostic value of simultaneous hybrid cardiac magnetic resonance (CMR) and F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection and differentiation of active (aCS) from chronic (cCS) cardiac sarcoidosis.
Background: Late gadolinium enhancement (LGE) CMR and FDG-PET are both established imaging techniques for the detection of CS. However, there are limited data regarding the value of a comprehensive simultaneous hybrid CMR/FDG-PET imaging approach that includes CMR mapping techniques.
Fibrin-Targeted PET/CMR in Atrial Fibrillation: First Steps Toward Imaging Thrombus Biology.
JACC Cardiovasc Imaging
March 2022
Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany.